SRPT Stock Analysis: Sarepta Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.782m USD | 12M Return: 2.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 52.7M
Qual. Beats: 1
Rev. Trend: 94.1%
Qual. Beats: 7
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sarepta Therapeutics is a Cambridge, Massachusetts-based commercial-stage biopharmaceutical company that develops RNA-targeted therapeutics, siRNA-based drugs, and gene therapies, with a focus on rare diseases. The company markets four approved treatments for Duchenne muscular dystrophy (DMD): EXONDYS 51, VYONDYS 53, and AMONDYS 45, which are exon-skipping therapies for patients with specific dystrophin gene mutations, and ELEVIDYS, an AAV-based gene therapy. Sarepta also has a clinical pipeline that includes SRP-9003 for LGMD2E, and two Phase 1/2a RNAi candidates, SRP-1001 and SRP-1003, targeting facioscapulohumeral muscular dystrophy and myotonic dystrophy, respectively. The company supports its development programs through a network of collaboration and license agreements with partners including Roche, Arrowhead Pharmaceuticals, Nationwide Childrens Hospital, Hansa Biopharma, and several academic institutions. Founded in 1980 and listed on NASDAQ under the ticker SRPT, Sarepta operates within the biotechnology subsector of healthcare, a segment where firms typically face long development timelines, significant regulatory risk, and dependence on a small number of approved products for revenue concentration.
- ELEVIDYS sales momentum and label expansion drive revenue
- Duchenne exon-skipping franchise faces competitive and pricing pressure
- FDA safety review on gene therapy clouds commercial outlook
| Net Income: 65.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 23.47 > 1.0 |
| NWC/Revenue: 82.90% < 20% (prev 81.80%; Δ 1.10% < -1%) |
| CFO/TA 0.06 > 3% & CFO 175.3m > Net Income 65.1m |
| Net Debt (582.0m) to EBITDA (125.0m): 4.66 < 3 |
| Current Ratio: 4.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (121.9m) vs 12m ago 25.22% < -2% |
| Gross Margin: 62.39% > 18% (prev 81.82%; Δ -19.42% > 0.5%) |
| Asset Turnover: 65.75% > 50% (prev 64.45%; Δ 1.30% > 0%) |
| Interest Coverage Ratio: 1.90 > 6 (EBIT TTM 79.8m / Interest Expense TTM 42.1m) |
| A: 0.57 (Total Current Assets 2.31b - Total Current Liabilities 499.2m) / Total Assets 3.18b |
| B: -1.43 (Retained Earnings -4.55b / Total Assets 3.18b) |
| C: 0.02 (EBIT TTM 79.8m / Avg Total Assets 3.32b) |
| D: 0.90 (Book Value of Equity 1.51b / Total Liabilities 1.67b) |
| Altman-Z'' = 0.18 = B |
| DSRI: 0.77 (Receivables 547.9m/724.5m, Revenue 2.18b/2.23b) |
| GMI: 1.31 (GM 81.82% / 62.39%) |
| AQI: 0.85 (AQ_t 0.13 / AQ_t-1 0.15) |
| SGI: 0.98 (Revenue 2.18b / 2.23b) |
| TATA: -0.03 (NI 65.1m - CFO 175.3m) / TA 3.18b) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of July 02, 2026, the stock is trading at USD 18.20 with a total of 3,364,743 shares traded. Over the past week, the price has changed by +8.98%, over one month by +3.35%, over three months by -17.76% and over the past year by +2.77%.
Current recommended Stop Loss: 17.20 (which is 5.5% or 1.1 ATR below the current price).
Sarepta Therapeutics has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy SRPT.
- StrongBuy: 14
- Buy: 8
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22 | 20.9% |
P/E Trailing = 48.2286
P/E Forward = 5.4795
P/S = 0.8145
P/B = 1.182
P/EG = 159.25
Revenue TTM = 2.18b USD
EBIT TTM = 79.8m USD
EBITDA TTM = 125.0m USD
Long Term Debt = 838.2m USD (from longTermDebt, last quarter)
Short Term Debt = 11.4m USD (from shortTermDebt, last fiscal year)
Debt = 1.24b USD (from shortLongTermDebtTotal, last quarter) + Leases 198.5m
Net Debt = 582.0m USD (calculated: Debt 1.24b - CCE 653.2m)
Enterprise Value = 2.36b USD (1.78b + Debt 1.24b - CCE 653.2m)
Interest Coverage Ratio = 1.90 (Ebit TTM 79.8m / Interest Expense TTM 42.1m)
EV/FCF = 22.27x (Enterprise Value 2.36b / FCF TTM 106.1m)
FCF Yield = 4.49% (FCF TTM 106.1m / Enterprise Value 2.36b)
FCF Margin = 4.86% (FCF TTM 106.1m / Revenue TTM 2.18b)
Net Margin = 2.98% (Net Income TTM 65.1m / Revenue TTM 2.18b)
Gross Margin = 62.39% ((Revenue TTM 2.18b - Cost of Revenue TTM 821.4m) / Revenue TTM)
Gross Margin QoQ = 83.67% (prev 9.98%)
Tobins Q-Ratio = 0.74 (Enterprise Value 2.36b / Total Assets 3.18b)
Interest Expense / Debt = 3.41% (Interest Expense 42.1m / Debt 1.24b)
Taxrate = 3.56% (12.2m / 343.2m)
NOPAT = 77.0m (EBIT 79.8m * (1 - 3.56%))
Current Ratio = 4.63 (Total Current Assets 2.31b / Total Current Liabilities 499.2m)
Debt / Equity = 0.82 (Debt 1.24b / totalStockholderEquity, last quarter 1.51b)
Debt / EBITDA = 4.66 (Net Debt 582.0m / EBITDA 125.0m)
Debt / FCF = 5.48 (Net Debt 582.0m / FCF TTM 106.1m)
Total Stockholder Equity = 1.33b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.96% (Net Income 65.1m / Total Assets 3.18b)
RoE = 4.89% (Net Income TTM 65.1m / Total Stockholder Equity 1.33b)
RoCE = 3.68% (EBIT 79.8m / Capital Employed (Equity 1.33b + L.T.Debt 838.2m))
RoIC = 2.98% (NOPAT 77.0m / Invested Capital 2.58b)
WACC = 6.82% (E(1.78b)/V(3.02b) * Re(9.27%) + D(1.24b)/V(3.02b) * Rd(3.41%) * (1-Tc(0.04)))
Discount Rate = 9.27% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 28.89 | Cagr: 6.60%
[DCF] Terminal Value 75.44% ; FCFF base≈106.1m ; Y1≈106.6m ; Y5≈112.9m
[DCF] Fair Price = 11.12 (EV 1.76b - Net Debt 582.0m = Equity 1.17b / Shares 105.6m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.53 | # QB: 1
Revenue Correlation: 94.14 | Revenue CAGR: 39.05% | SUE: 4.0 | # QB: 7
EPS current Quarter (2026-09-30): EPS=0.50 | Chg30d=-18.08% | Revisions=-8% | Analysts=9
EPS current Year (2026-12-31): EPS=4.83 | Chg30d=+20.94% | Revisions=+38% | GrowthEPS=+195.6% | GrowthRev=-16.4%
EPS next Year (2027-12-31): EPS=2.73 | Chg30d=-9.30% | Revisions=-12% | GrowthEPS=-43.6% | GrowthRev=-22.5%
[Analyst] Revisions Ratio: +38%